<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>L1, a neuronal cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> receptor of the immunoglobulin-like protein family is expressed in invading <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) cells as a target gene of Wnt/β-catenin signaling </plain></SENT>
<SENT sid="1" pm="."><plain>Overexpression of L1 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells enhances cell motility and proliferation, and confers <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We recently identified ezrin and the IκB-NF-κB pathway as essential for the biological properties conferred by L1 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we studied the underlying molecular mechanisms and found that L1 enhances ezrin phosphorylation, via Rho-associated protein kinase (ROCK), and is required for L1-ezrin co-localization at the juxtamembrane domain and for enhancing cell motility </plain></SENT>
<SENT sid="4" pm="."><plain>Global transcriptomes from L1-expressing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells were compared with transcriptomes from the same cells expressing small hairpin <z:chebi fb="40" ids="33697">RNA</z:chebi> (shRNA) to ezrin </plain></SENT>
<SENT sid="5" pm="."><plain>Among the genes whose expression was elevated by L1 and ezrin we identified insulin-like growth factor-binding protein 2 (IGFBP-2) and showed that its increased expression is mediated by an NF-κB-mediated transactivation of the IGFBP-2 gene promoter </plain></SENT>
<SENT sid="6" pm="."><plain>Expression of a constitutively activated mutant ezrin (Ezrin567D) could also increase IGFBP-2 levels in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="7" pm="."><plain>Overexpression of IGFBP-2 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells lacking L1-enhanced cell proliferation (in the absence of serum), cell motility, <z:mp ids='MP_0002006'>tumorigenesis</z:mp> and induced <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e>, similar to L1 overexpression </plain></SENT>
<SENT sid="8" pm="."><plain>Suppression of endogenous IGFBP-2 in L1-transfected cells inhibited these properties conferred by L1 </plain></SENT>
<SENT sid="9" pm="."><plain>We detected IGFBP-2 in a unique organization at the bottom of human colonic crypts in <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa and at increased levels throughout human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissue samples co-localizing with the phosphorylated p65 subunit of NF-κB </plain></SENT>
<SENT sid="10" pm="."><plain>Finally, we found that IGFBP-2 and L1 can form a molecular complex suggesting that L1-mediated signaling by the L1-ezrin-NF-κB pathway, that induces IGFBP-2 expression, has an important role in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> progression.Oncogene advance online publication, 6 August 2012; doi:10.1038/onc.2012.340 </plain></SENT>
</text></document>